Tenax Therapeutics to amend Level-2 enrollment criteria
TENX•Tenax Therapeutics will amend Level-2 enrollment criteria, has requested a Type C meeting with the FDA on levosimendan development and temporarily paused Level-2 enrollment for TNX-103 in PH-HFpEF. Enrollment may resume at each site as the amended protocol takes effect.
1. Enrollment changes
Tenax Therapeutics said in an SEC filing that it will amend Level-2 enrollment criteria and has temporarily paused Level-2 enrollment for TNX-103 in PH-HFpEF. The company requested a Type C meeting with the FDA on levosimendan development. Enrollment may resume at each site as the amended protocol takes effect.
